|

Mercaptopurine Clinical Trials

16 actively recruiting trials across 6 locations

Also known as: 3H-Purine-6-thiol, 6 MP, 6 Thiohypoxanthine, 6 Thiopurine, 6-MP +33 more

Pipeline

Phase 1: 2Phase 2: 9Phase 3: 2Phase 1/2: 2

Top Sponsors

  • M.D. Anderson Cancer Center5
  • National Cancer Institute (NCI)3
  • City of Hope Medical Center2
  • University of Chicago1
  • Tanja Andrea Gruber1

Indications

  • Cancer16
  • B Acute Lymphoblastic Leukemia5
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative2
  • Recurrent B Acute Lymphoblastic Leukemia2
  • B Lymphoblastic Lymphoma2

Houston, Texas5 trials

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M D Anderson Cancer Center

Phase 2
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M D Anderson Cancer Center

Phase 1/2
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M D Anderson Cancer Center

Phase 2
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

M D Anderson Cancer Center

Phase 2

Birmingham, Alabama4 trials

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 3
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Children's Hospital of Alabama

Phase 2
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Hospital of Alabama

Phase 3
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Children's Hospital of Alabama

Phase 2

Other2 trials

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Phase 2

Phoenix, Arizona2 trials

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

City of Hope at Phoenix

Phase 2
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Phoenix Children's Hospital

Phase 1/2

Duarte, California1 trial

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

City of Hope Medical Center

Phase 1

San Diego, California1 trial

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Rady Children's Hospital

Phase 2

Chicago, Illinois1 trial

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

University of Chicago Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.